36 results

• Dupixent Sales Surge Amid Growing CTCL Cancer Lawsuit Allegations

  October 29, 2025

  Irvin Jackson

  Sanofi indicates Dupixent sales are growing stronger as the medication gathers more indications for use worldwide, despite recent cancer concerns.

• Dupixent Lawyers To Meet With Court for Initial Conference in T-Cell Lymphoma Lawsuit

  October 17, 2025

  Irvin Jackson

  Parties involved in a Dupixent T-cell lymphoma wrongful death lawsuit will participate in an initial status conference in early December, to map out how the litigation will move forward.

• Dupixent Wrongful Death Lawsuit Filed Over T-Cell Lymphoma Diagnosis

  October 2, 2025

  Irvin Jackson

  A Dupixent lawsuit blames the atopic dermatitis drug for causing a woman to develop a deadly form of cancer, which caused her death.

• Dupixent Side Effects May Increase Cutaneous T-Cell Lymphoma (CTCL) Risks

  August 26, 2025

  Irvin Jackson

  Recent studies warn that the eczema treatment Dupixent appears to significantly increase the risk of cutaneous T-cell lymphoma (CTCL).

• Study Questions Whether Side Effects of Xeljanz, Similar Drugs, Increase Blood Clot Risks

  September 8, 2022

  Irvin Jackson

  A new study raises doubts about whether Xeljanz and similar drugs increase the risk of blood clots.

• Makers of Oluminant Withdraw Lupus Treatment Approval Request in Face of JAK-Inhibitor Health Risks

  January 31, 2022

  Irvin Jackson

  A request for approval for Olumiant to treat lupus has been withdrawn, and the manufacturers expect the FDA to reject an atopic dermatitis approval request in the face of growing concerns over the side effects of similar arthritis drugs like Xeljanz.